AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 NOV 14 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - U.S. researchers have determined two important chemokines can increase the effectiveness of vaccines containing DNA and other genetic material.
Scientists at the University of Tennessee, Knoxville, have found that secondary lymphoid tissue chemokine (SLC) and Epstein-Barr virus-induced molecule 1 ligand chemokine (ELC) augment the effectiveness of herpes simplex virus DNA vaccines. These chemokines, codelivered via plasmid DNA, might be an important adjuvant for genetic vaccines used to battle other infectious diseases or cancer, researchers propose.
Both SLC and ELC pave the way for effective immune response mechanisms by modifying the microenvironment, S.K. Eo and colleagues said. Tests performed by these researchers were designed in order to understand how coadministration of the two CRR7 ligands would facilitate microenvironment modification when vaccine delivery scenarios were changed.
"Systemic co-transfer of both CCR7 ligands enhanced serum gB-specific Ig (immunoglobulin) G Ab (antibody) but failed to elicit enhancement of distal mucosal IgA responses. In contrast, mucosal co-transfer provided significant increases of distal mucosal IgA responses," Eo and associates said.
Eo and coworkers also determined T-cell response was heightened after vaccine/chemokine codelivery. ...
Source: HighBeam Research, CRR7 Ligands Heighten Gene Vaccine Effectiveness.(Brief Article)